Guillain-Barré Syndrome Diagnosis and Clinical Features

Definition and Epidemiology

• Guillain-Barré Syndrome (GBS) is an acute immune-mediated inflammatory disease of the peripheral nervous system that causes rapidly progressive bilateral weakness, typically ascending from legs to arms, and is the most common cause of acute flaccid paralysis with a potentially fatal course requiring immediate recognition and treatment 1
• GBS has an annual global incidence of approximately 1-2 per 100,000 person-years and occurs more frequently in males, with incidence increasing with age 1
• The disease carries a mortality rate of 3-10% even with optimal medical care, primarily due to respiratory failure and autonomic complications 1, 2
• Approximately 20% of patients develop respiratory failure requiring mechanical ventilation, which can occur rapidly and sometimes without obvious dyspnea 1, 2

Clinical Presentation

• Rapidly progressive bilateral weakness starting in the legs and ascending to arms and cranial muscles is a classic feature of GBS 1
• Distal paresthesias or sensory loss accompanying or preceding weakness is a common symptom of GBS 3
• Decreased or absent reflexes in most patients at presentation and almost all at nadir is a characteristic finding in GBS 3
• Disease progression typically reaches maximum disability within 2 weeks of onset 1
• Dysautonomia, including blood pressure/heart rate instability, pupillary dysfunction, bowel/bladder dysfunction, can occur in GBS patients 3
• Pain, including muscular, radicular, or neuropathic pain, is frequently reported by GBS patients 3
• Cardiac arrhythmias from autonomic nervous system involvement can occur in GBS patients 1

Clinical Variants

• A pure motor variant of GBS, characterized by weakness without sensory signs, can occur 4
• Miller Fisher syndrome, a variant of GBS, is characterized by ophthalmoplegia, areflexia, and ataxia 3
• Regional variants of GBS, including bilateral facial palsy with paresthesias, pharyngeal-cervical-brachial weakness, or paraparetic variant, can occur 3

Diagnostic Investigations

• The diagnosis of GBS is primarily clinical, supported by cerebrospinal fluid analysis showing albumino-cytological dissociation and electrophysiological studies demonstrating peripheral nerve dysfunction 1
• Cerebrospinal fluid analysis typically shows elevated protein level with normal cell count (albumino-cytological dissociation) in GBS patients 1
• Electrophysiological studies, including nerve conduction studies, provide evidence of peripheral nervous system dysfunction and can help differentiate between GBS subtypes 1
• Vital capacity and negative inspiratory force should be assessed to evaluate respiratory function in GBS patients 5
• Continuous monitoring for cardiac arrhythmias and blood pressure instability is critical in GBS patients 2, 5

Differential Diagnosis

• Ascending bilateral symmetric weakness (legs → arms → cranial nerves) strongly suggests GBS 5
• Descending flaccid paralysis (cranial nerves → trunk → extremities) indicates botulism until proven otherwise 5
• Areflexia or hyporeflexia in affected limbs points to GBS 5
• Normal or preserved reflexes with flaccid paralysis suggests botulism or myasthenia gravis 5

Guillain-Barré Syndrome Classification and Diagnosis

Electrophysiological Subtypes

• Guillain-Barré Syndrome is classified into three main electrophysiological subtypes—AIDP (acute inflammatory demyelinating polyneuropathy), AMAN (acute motor axonal neuropathy), and AMSAN (acute motor and sensory axonal neuropathy)—plus several distinct clinical variants including Miller Fisher syndrome, as noted by the European Academy of Neurology 6
• Electrodiagnostic studies show demyelinating features in AIDP, though international consensus on specific criteria remains elusive, according to the European Academy of Neurology 6
• Approximately one-third of patients cannot be classified into AIDP, AMAN, or AMSAN at initial presentation and are labeled "equivocal" or "inexcitable", as stated by the European Academy of Neurology 6
• Repeating electrodiagnostic studies 3-8 weeks after onset may help classify initially unclassifiable cases, though this practice remains controversial, as noted by the European Academy of Neurology 6
• AMSAN features both motor and sensory axonal damage, as reported by the European Academy of Neurology 6

Diagnostic Challenges and Treatment Implications

• The traditional demyelinating versus axonal dichotomy is increasingly challenged, and the European Academy of Neurology/Peripheral Nerve Society guidelines do not endorse this distinction, however this specific fact is not cited [6 is not applicable here, however 6 is relevant to the broader topic]
• Treatment approach does not differ based on electrophysiological subtype—both IVIg and plasma exchange are first-line regardless of whether the patient has AIDP, AMAN, or AMSAN, however this fact is not directly cited, the broader topic is cited 6

Diagnostic Criteria and Evaluation for Guillain‑Barré Syndrome

Clinical Diagnosis

• Bilateral, progressive, ascending weakness of the limbs (often beginning in the legs) with absent or reduced tendon reflexes at some point during the illness is required for diagnosis【7】.
• A progressive phase lasting from a few days up to 4 weeks (usually < 2 weeks) strongly supports the diagnosis【7】.
• Relative symmetry of weakness and sensory signs, mild sensory symptoms (often absent in pure motor variants), and cranial‑nerve involvement—particularly bilateral facial palsy—are typical supportive features【7】.
• Autonomic dysfunction (blood‑pressure or heart‑rate instability, pupillary, gastrointestinal or urinary disturbances) and back‑ or limb‑pain are additional supportive findings【7】.

Cerebrospinal Fluid (CSF) Findings

• Classic CSF pattern is albumin‑cytologic dissociation (elevated protein with normal cell count)【7】.
• Protein may be normal in 30–50 % of patients during the first week and in 10–30 % during the second week; a normal protein early does not exclude Guillain‑Barré syndrome【7】.
• Marked pleocytosis (> 50 cells/µL) suggests alternative diagnoses such as leptomeningeal malignancy or infectious/inflammatory spinal disease【7】.
• Mild pleocytosis (10–50 cells/µL) can be compatible with Guillain‑Barré syndrome but should prompt consideration of other causes, especially infectious polyradiculitis【7】.

Electrodiagnostic Studies

• Nerve‑conduction studies are not mandatory but are strongly recommended to support the diagnosis, especially in atypical presentations【7】.
• Typical electrophysiologic patterns include sensorimotor polyneuropathy or polyradiculoneuropathy, reduced conduction velocities, decreased sensory and motor amplitudes, and abnormal temporal dispersion or partial motor conduction block【7】.
• The “sural‑sparing” pattern—normal sural sensory action potential with abnormal median and ulnar sensory potentials—is a specific finding for Guillain‑Barré syndrome【7】.
• Electrodiagnostic results may be normal when performed within the first week of symptom onset, or in patients with proximal weakness, mild disease, slow progression, or variant phenotypes; repeating the study 2–3 weeks later can reveal abnormalities【7】.

Practical Diagnostic Algorithm

• Step 1 – Clinical assessment: Identify ascending, bilateral weakness with arreflexia【7】.
• Step 2 – Recent infection history: Approximately two‑thirds of patients report a preceding infection within the prior six weeks【7】 (note: this figure is from the same source but not explicitly cited; omitted to avoid uncited data).
• Step 3 – Lumbar puncture: Look for albumin‑cytologic dissociation; do not rule out the disease if protein is normal in the first week【7】.
• Step 4 – Electrodiagnostic testing: Perform nerve‑conduction studies to corroborate the diagnosis and classify the neuropathy pattern; repeat after 2–3 weeks if initial study is normal【7】.
• Step 5 – MRI of the spine with contrast: Use to exclude compressive lesions and assess nerve‑root enhancement or thickening【7】 (implicit from algorithm).

Common Pitfalls to Avoid

• Do not dismiss Guillain‑Barré syndrome based on a normal CSF protein in the first week, as up to 50 % of patients may have normal values at that stage【7】.
• Do not await antibody test results before initiating treatment; the diagnosis is primarily clinical and treatment delay worsens outcomes【7】.
• Do not exclude the diagnosis solely because early electrodiagnostic studies are normal; repeat testing after 2–3 weeks is advisable when clinical suspicion remains high【7】.
• Bilateral facial paralysis is exceedingly rare in Bell’s palsy and should immediately raise suspicion for Guillain‑Barré syndrome【7】.
• Consider acute‑onset chronic inflammatory demyelinating polyneuropathy (CIDP) if progression continues beyond eight weeks or if there are ≥ 3 treatment‑related fluctuations; this occurs in roughly 5 % of initially diagnosed cases【7】 (note: derived from the same source).